Centene Corp

CNC: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
q<@LOCK|y%>LOCK|%&NXMBw

Centene Earnings: Rising Medical Costs Constrain 2025 Outlook, but Growth Expected in 2026

After withdrawing 2025 guidance in early July due primarily to challenges in the individual exchange market, Centene turned in a second-quarter loss after its medical loss ratio ballooned to 93%, despite 18% growth in premium and service revenue. Guidance for 2025 now includes $1.75 of adjusted EPS.

Sponsor Center